NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Price Target & More

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Monday, April, 30th. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.18. The business earned $71.08 million during the quarter, compared to the consensus estimate of $65.17 million. Neurocrine Biosciences had a negative return on equity of 29.67% and a negative net margin of 45.56%. During the same quarter in the previous year, the company earned ($0.90) earnings per share. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Neurocrine Biosciences.

13 analysts have issued 1 year price objectives for Neurocrine Biosciences' shares. Their predictions range from $79.00 to $127.00. On average, they expect Neurocrine Biosciences' share price to reach $104.6154 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Ratings for Neurocrine Biosciences.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Momenta Pharmaceuticals (MNTA).

News headlines about NBIX stock have trended somewhat positive recently, Accern reports. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.08 on Accern's scale. They also gave press coverage about the company an impact score of 46.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Neurocrine Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Handelsbanken Fonder AB (0.18%), Mckinley Capital Management LLC Delaware (0.14%), Fisher Asset Management LLC (0.03%), Xact Kapitalforvaltning AB (0.01%), State of Alaska Department of Revenue (0.01%) and Rockland Trust Co. (0.00%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Stephen A Sherwin, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB and NN Investment Partners Holdings N.V.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Stephen A Sherwin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

NBIX stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Rockland Trust Co., State of Alaska Department of Revenue, Mckinley Capital Management LLC Delaware and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $104.54.

Neurocrine Biosciences has a market capitalization of $9.25 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]